Core Insights - Silo Pharma, Inc. announced promising results from sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain, indicating stability and consistent drug release [1][2] - The SP-26 implant demonstrated over 80% drug release over a 7-day period, highlighting its effective time-release formulation [2] - The company is also developing SPC-15, a novel serotonin 4 receptor agonist for PTSD and anxiety, which may qualify for the FDA's streamlined 505(b)(2) regulatory pathway [3] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on novel therapeutics for underserved conditions, including chronic pain and stress-induced psychiatric disorders [3] - The company's lead programs include SP-26 for chronic pain relief and SPC-15 for PTSD, with additional preclinical programs targeting Alzheimer's disease and multiple sclerosis [3]
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant